Corline Biomedical Q4: Focus on Kardium’s market launch - Redeye
Bildkälla: Stockfoto

Corline Biomedical Q4: Focus on Kardium’s market launch - Redeye

Redeye provides an update following Corline’s Q4 2024 report. The report itself was relatively undramatic; however, we look forward to an eventful 2025. We make some model changes, but our fair value range remains intact.

Redeye provides an update following Corline’s Q4 2024 report. The report itself was relatively undramatic; however, we look forward to an eventful 2025. We make some model changes, but our fair value range remains intact.
Börsvärldens nyhetsbrev
ANNONSER